ZBH241220P100000
- 0.15
- 0.000.00%
Zimmer Biomet Holdings Newsroom
Morgan Stanley Initiates Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Announces Target Price $115
Wells Fargo Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $117
Hold Rating for Zimmer Biomet Holdings Amid Uncertain Impact of New Product Launch in US Market
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $117
Zimmer Biomet Holdings Is Maintained at Outperform by RBC Capital
Zimmer Biomet Holdings Analyst Ratings
RBC Capital Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Raises Target Price to $125
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Viridian Therapeutics (VRDN) and Select Medical (SEM)
RBC Capital Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Announces Target Price $117
Truist Securities Maintains Hold on Zimmer Biomet Holdings, Raises Price Target to $117
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $117 to $140
Zimmer Biomet Holdings Is Maintained at Equal-Weight by Wells Fargo
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $117 to $140
Zimmer Biomet Holdings Analyst Ratings
Morgan Stanley Adjusts Zimmer Biomet Holdings' Price Target to $122 From $118, Keeps Equalweight Rating
JMP Securities Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Maintains Target Price $140
JMP Securities Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Maintains Target Price $140
Oppenheimer Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Cuts Target Price to $135
Oppenheimer Adjusts Price Target on Zimmer Biomet to $135 From $145